Artesunate: could be an alternative drug to chloroquine in COVID-19 treatment?

Uzun, Tuğçenur; Toptaş, Orçun

doi:10.1186/s13020-020-00336-8

Cited by 41 publications

(47 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our analysis, we found that Artenimol or Artesunate, an alternative of Chloroquine could also be effective in treating COVID-19. Moreover, Artesunate was previously predicted to be a good candidate against SARS-CoV-2 [ 56 , 57 ] and is currently under clinical trial (NCT04387240).…”

Section: Discussionmentioning

confidence: 99%

Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19

Barh

Tiwari

Weener³

et al. 2020

Computers in Biology and Medicine

View full text Add to dashboard Cite

SARS-CoV-2 has ushered a global pandemic with no effective drug being available at present. Although several FDA-approved drugs are currently under clinical trials for drug repositioning, there is an on-going global effort for new drug identification. In this paper, using multi-omics (interactome, proteome, transcriptome, and bibliome) data and subsequent integrated analysis, we present the biological events associated with SARS-CoV-2 infection and identify several candidate drugs against this viral disease. We found that: (i) Interactome-based infection pathways differ from the other three omics-based profiles. (ii) Viral process, mRNA splicing, cytokine and interferon signaling, and ubiquitin mediated proteolysis are important pathways in SARS-CoV-2 infection. (iii) SARS-CoV-2 infection also shares pathways with Influenza A, Epstein-Barr virus, HTLV-I, Measles, and Hepatitis virus. (iv) Further, bacterial, parasitic, and protozoan infection pathways such as Tuberculosis, Malaria, and Leishmaniasis are also shared by this virus. (v) A total of 50 candidate drugs, including the prophylaxis agents and pathway specific inhibitors are identified against COVID-19. (vi) Betamethasone, Estrogen, Simvastatin, Hydrocortisone, Tositumomab, Cyclosporin A etc. are among the important drugs. (vii) Ozone, Nitric oxide, plasma components, and photosensitizer drugs are also identified as possible therapeutic candidates. (viii) Curcumin, Retinoic acids, Vitamin D, Arsenic, Copper, and Zinc may be the candidate prophylaxis agents. Nearly 70% of our identified agents are previously suggested to have anti-COVID-19 effects or under clinical trials. Among our identified drugs, the ones that are not yet tested, need validation with caution while an appropriate drug combination from these candidate drugs along with a SARS-CoV-2 specific antiviral agent is needed for effective COVID-19 management.

show abstract

Section: Discussionmentioning

confidence: 99%

Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19

Barh

Tiwari

Weener³

et al. 2020

Computers in Biology and Medicine

View full text Add to dashboard Cite

show abstract

“…In response to previous success stories in COVID-19 clinical case management in various parts of the world, the anti-malarial drugs chloroquine, hydroxychloroquine and artemisinin-based therapy have been widely used to treat the patients diagnosed with COVID-19 in addition to standard supportive care [ 13 , 14 ]. Reports of bulk procurement from foreign pharmaceutical companies and third-party wholesale distributors by the government or people in panic, have resulted in global shortage of anti-malarial drugs [ 15 ].…”

Section: Main Textmentioning

confidence: 99%

Addressing budget reduction and reallocation on health-related resources during COVID-19 pandemic in malaria-endemic countries

Diptyanusa

Zablon

2020

Malar J

View full text Add to dashboard Cite

The global COVID-19 pandemic has been affecting the maintenance of various disease control programmes, including malaria. In some malaria-endemic countries, funding and personnel reallocations were executed from malaria control programmes to support COVID-19 response efforts, resulting mainly in interruptions of disease control activities and reduced capabilities of health system. While it is principal to drive national budget rearrangements during the pandemic, the long-standing malaria control programmes should not be left behind in order to sustain the achievements from the previous years. With different levels of intensity, many countries have been struggling to improve the health system resilience and to mitigate the unavoidable stagnation of malaria control programmes. Current opinion emphasized the impacts of budget reprioritization on malaria-related resources during COVID-19 pandemic in malaria endemic countries in Africa and Southeast Asia, and feasible attempts that can be taken to lessen these impacts.

show abstract

“…Artemisinin has a clinical impact potential in the treatment of COVID-19 because it can prevent the progression of the disease and accelerate the recovery of patients before they develop potentially life-threatening complications ( Uzun and Toptas, 2020 ; Krishna et al, 2021 ). This dual-function COVID-19 drug candidate is hoped to mitigate the cytokine-mediated inflammatory injury associated with the cytokine storm and viral sepsis in critically ill COVID-19 patients.…”

Section: Discussionmentioning

confidence: 99%

Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug

Uckun¹,

Saund²,

Windlass³

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Artemisinin is an anti-inflammatory phytomedicine with broad-spectrum antiviral activity. Artemisinin and its antimalarial properties were discovered by the Chinese scientist Tu Youyu, who became one of the laureates of the 2015 Nobel Prize in Physiology or Medicine for this breakthrough in tropical medicine. It is a commonly used anti-malaria drug. Artemisinin has recently been repurposed as a potential COVID-19 drug. Its documented anti-SARS-CoV-2 activity has been attributed to its ability to inhibit spike-protein mediated and TGF-β-dependent early steps in the infection process as well as its ability to disrupt the post-entry intracellular events of the SARS-CoV-2 infection cycle required for viral replication. In addition, Artemisinin has anti-inflammatory activity and reduces the systemic levels of inflammatory cytokines that contribute to cytokine storm and inflammatory organ injury in high-risk COVID-19 patients. We postulate that Artemisinin may prevent the worsening of the health condition of patients with mild-moderate COVID-19 when administered early in the course of their disease.

show abstract

Artesunate: could be an alternative drug to chloroquine in COVID-19 treatment?

Cited by 41 publications

References 39 publications

Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19

Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19

Addressing budget reduction and reallocation on health-related resources during COVID-19 pandemic in malaria-endemic countries

Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug

Contact Info

Product

Resources

About